Indicators on Clinical trial recruitment for ABBV-744 study You Should Know
In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Contributors will acquire treatment till disease progression or perhaps the contributors are not able to tolerate the study drugs.For all flow cytometry experiments, 10,000 cells for every replicate ended up analyzed, and thr